Revolutionizing the Cancer Battle: DCTD's Innovative Drug Discovery, Novel Therapies and Future of Cancer Treatment

Revolutionizing the Cancer Battle: DCTD’s Innovative Drug Discovery, Novel Therapies and Future of Cancer Treatment

The Division of Cancer Treatment and Diagnosis (DCTD) is driving cancer research through innovative drug discovery, new treatments, and advanced strategies. Key developments include the modernization of the NCI-60 Human Tumor Cell Lines Screen, which has improved the evaluation process for potential cancer treatments. DCTD is also making strides in personalized medicine through the Experimental Therapeutics Clinical Trials Network (ETCTN), which crafts therapies based on individual patient's tumor genetics.

Further initiatives from DCTD include facilitating rapid research access to agents through the NCI Formulary and testing new drug combinations through the NCI ComboMATCH initiative. The Quantitative Imaging Network (QIN) and the NCI Patient-Derived Models Repository are contributing to the evolution of precision diagnostics. Several advancements, such as Blinatumomab for Acute Lymphoblastic Leukemia in infants, a new treatment method for advanced colorectal cancer, and Pembrolizumab's efficacy for a rare melanoma type, highlight DCTD's commitment to redefining cancer treatment.

Full article here: https://medium.com/@lawsuithelpdesk/revolutionizing-the-cancer-battle-dctds-innovative-drug-discovery-novel-therapies-and-future-of-c15bd73d80d8